Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRO D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL FORTE versus HYDRO D.
ENDURONYL FORTE vs HYDRO-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enduronyl Forte is a combination of methyclothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, and deserpidine, a Rauwolfia alkaloid that depletes catecholamines from adrenergic nerve endings, resulting in reduced peripheral vascular resistance and CNS sedation.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Oral: Initial 2.5-5 mg once daily; increase as needed to maximum 20 mg once daily.
25-100 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (avg. 36 h); due to long half-life, requires caution in renal impairment.
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Renal: ~50% unchanged; Biliary/Fecal: ~50% as metabolites and unchanged drug.
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic